Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage IV Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT01327781
What this trial is testing

Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

Who this might be right for
HER2/Neu PositiveRecurrent Breast CarcinomaStage IIIC Breast Cancer AJCC v7+1 more
National Cancer Institute (NCI) 62
Not applicableStudy completedNCT03730428
What this trial is testing

Everolimus Related Pneumonitis in MBC

Who this might be right for
EverolimusPneumonitis
Fudan University 86
Testing effectiveness (Phase 2)Study completedNCT00951665
What this trial is testing

Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 107
Large-scale testing (Phase 3)Ended earlyNCT00272987
What this trial is testing

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 63
Testing effectiveness (Phase 2)Study completedNCT00106002
What this trial is testing

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast Neoplasms, MaleCarcinoma, Ductal
Eli Lilly and Company 37
Early research (Phase 1)Ended earlyNCT02512237
What this trial is testing

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Who this might be right for
Breast NeoplasmsStomach Neoplasms
Zhejiang Medicine Co., Ltd. 9
Large-scale testing (Phase 3)Looking for participantsNCT05950945
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Daiichi Sankyo 250
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Testing effectiveness (Phase 2)UnknownNCT00416130
What this trial is testing

Clinical Trial of SAHA in Patients With Breast Cancer

Who this might be right for
Breast Cancer
National University Hospital, Singapore 49
Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)WithdrawnNCT06938711
What this trial is testing

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07545044
What this trial is testing

JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc. 60
Not applicableLooking for participantsNCT06121453
What this trial is testing

Adherence Intervention in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Columbia University 35
Not applicableUnknownNCT05919212
What this trial is testing

Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

Who this might be right for
Metastatic Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 22
Not applicableStudy completedNCT06655545
What this trial is testing

18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Fudan University 473
Testing effectiveness (Phase 2)Study completedNCT00431067
What this trial is testing

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 41
Testing effectiveness (Phase 2)Ended earlyNCT00110136
What this trial is testing

St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer

Who this might be right for
Breast CancerHot Flashes
Wake Forest University Health Sciences 9
Testing effectiveness (Phase 2)Ended earlyNCT03130439
What this trial is testing

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 27
Testing effectiveness (Phase 2)Ended earlyNCT00427427
What this trial is testing

Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 75
Not applicableStudy completedNCT00226928
What this trial is testing

Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer

Who this might be right for
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
Stanford University 125
Next Page